Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications

a technology of tgf-beta and protein fraction, applied in the field of tgf-beta factor purification, can solve the problems of reducing the final yield, long and tedious tgf-beta purification process, and not having a process to purify tgf-beta

Inactive Publication Date: 2005-11-10
PIERRE JOUAN BIOTECH
View PDF9 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But preparations containing TGF-beta recombinants are susceptible to contain some bacterial proteins, of which some are allergenic.
In addition, by definition, purified preparations of TGF-beta recombinants do not contain associated milk proteins which can complete or increase the TGF-beta biological effect.
However, this process, which is able to eliminate casein from the initial skimmed milk, is not a process to purify TGF-beta.
As a matter of fact, TGF-beta purification processes involving successive chromatographic steps are long and tedious.
The important number of chromatographic steps necessary for achieving a desired degree of purity considerably decreases the final yield because of the progressive TGF-beta degradation while purification is carrying out, and the unavoidable loss of biologically active TGF-beta at each of the chromatography steps.
In addition to the use of different saline and highly polluting regeneration solutions that must thereafter be eliminated, these processes present a high risk of bacterial contamination of the final product.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
  • Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications

Examples

Experimental program
Comparison scheme
Effect test

example i

Preparation of a Solution Rich in Whey Proteins (WPI) as a Starting Product for the Process According to the Invention

[0166] 10,000 Kg of skimmed milk with a content in dry matter of 92.9 g / Kg and a content in N×6.38 of 35.4 g / Kg were introduced, at 50° C., in a microfiltration equipment comprising a 4.6 m2 and 0.1 μm Membralo® membrane (alumine-zircone) and functioning with co-current recirculation of the microfiltrate such as to obtain a uniform transmembrane pressure of 0.6 to 0.7 bars.

[0167] The scanning rate in the Retentate compartment was fixed at 7 m / s.

[0168] The microfiltrate extraction flux was fixed at 345 l / h. The retentate extraction flux was fixed at 172.5 l / h.

[0169] The 6670 l of microfiltrate obtained, with a content in dry matter of 57.8 g / Kg and a content in N×6.38 of 6.4 g / Kg, were cooled down at 10° C. and introduced in an ultrafiltration equipment comprising a 9.6 m2 Koch® membrane, with a spiral conception, and having a cut-off of 5 Kd. The outlet pressure...

example ii

Preparation of a Fraction Highly Enriched in TGF-Beta Starting from a Solution Rich in Whey Proteins

[0172] 200 Kg of the diafiltered retentate obtained according to Example I were diluted in 2000 l with osmosis water at a temperature of 20° C. in a tank equipped with a balde agitator.

[0173] After 10 minutes of stirring, 1800 ml of 6N HCl were progressively added until the lowering of the pH value from 7.25 to 4.6. Stirring was continued during 10-15 minutes. The solution was thermally treated at 63° C.-2 minutes and cooled down at 25° C. in an Actijoulee equipment by 1000 l aliquots. The 2000 l of the obtained suspension, heated at 35° C., were then microfiltered in continuous in an equipment with 4.6 m2 STERILOX® membranes having a 1.4 μm average pore diameter with co-current recirculation of the microfiltrate in a manner to obtain a uniform transmembrane pressure between 0.4 and 0.8 bars in 4.5 hours.

[0174] The extraction flux of the microfiltrate was fixed at 400 l / h. No extr...

example iii

Quantitative and Qualitative Analysis of the Protein Fraction Highly Enriched in TGF-Beta According to the Invention

[0177] 1 mg of the lyophilized powder obtained in the Example II was dissolved in 1 ml of milliQ water then diluted 5 times in buffer A. The analytical equipment used was a Waters 600 E HPLC chromatograph with a “source RPC 3 ml” column (Pharmacia®).

[0178] The two buffers used were: [0179] Buffer A: Trifluoroacetic acid (TFA) 0.1%, and [0180] Buffer B: TFA 0.09% in acetonitrile 90%.

[0181] 50 μl of product were injected and the elution was carried out by a gradient of 30 to 100% of buffer B in 30 minutes with a flux of 2 ml / min (at room temperature). Detection was carried out at 214 nm. Treatment of chromatographic areas was carried out with a Nelson® software, which allowed the estimation of the content, when compared to the total proteins: 53% of alpha-lactalbumin, 0.03% of serum-albumin, 10.9% of beta-lactoglobulin and 18.3% of immunoglobulins.

[0182] The TGF-bet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk and / or of whey, said method comprising the following steps; a) adjusting soluble proteins purified at a concentration between 5 and 30 g / liter of solution; b) precipitating part of the whey proteins by acidic treatment of the solution thus obtained to a pH ranging between 4 and 5.5 and at a temperature ranging between 55° C. and 68° C.; c) carrying out a microfiltration of the treated solution by diafiltration, so as to obtain respectively a microfiltration retentate and a microfiltrate; d) recuperating the microfiltration retentate containing the protein fraction highly enriched in TGF-beta; e) drying the microfiltration retentate which has been subjected to diafiltration to obtain a powder highly enriched in TGF-beta.

Description

RELATIONSHIP TO PRIOR APPLICATION [0001] This application is a divisional of U.S. patent application Ser. No. 10 / 469,530, having a 371 (c) date of Dec. 22, 2003, which is the National Stage of PCT / FR02 / 02489 filed Jul. 12, 2002.BACKGROUND OF THE INVENTION [0002] 1. Technical Field [0003] This invention relates to the field of TGF-beta factor purification from a dairy source. [0004] 2. Description of Prior Art [0005] Milk, in particular human and mammal milk, contains several bioactive polypeptides, especially numerous growth factors. One of these growth factors contained in milk is TGF-beta (Transforming Growth Factor beta). [0006] The term TGF-beta designates a family of different growth factors. TGF-beta 1 and TGF-beta 2 are two homologous forms of TGF-beta. They are homodimeric constituents made up of two similar polypeptide chains each containing 112 amino-acids, linked by a disulfide bridge. Their molecular mass is 25,000 Daltons. TGF-beta 1 and TGF-beta 2 have 72% of structura...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A23J1/20A61K35/20A61K38/00A61K38/18A61P1/04A61P17/02A61P17/06A61P19/02A61P19/10A61P21/04A61P29/00A61P35/00A61P37/02A61P37/06B01D61/14B01D61/16B01D61/58C07K14/495
CPCA23J1/205A23V2002/00A61K35/20A61K38/1841Y10S930/12C07K14/495A23V2300/34A23V2300/40A61P1/04A61P17/02A61P17/06A61P19/02A61P19/10A61P21/04A61P29/00A61P35/00A61P37/02A61P37/06
Inventor MAUBOIS, JEAN-LOUISFAUQUANT, JACQUESJOUAN, PIERREBOURTOURAULT, MICHEL
Owner PIERRE JOUAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap